Smart monitoring for men with advanced prostate cancer
Part of Cancer clinical trials.
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have prostate cancer that has spread to other parts of the body (metastatic).
- Your cancer is sensitive to hormones—meaning it can be treated with hormone therapy.
- Your testosterone level is above 50 ng/dL before starting hormone therapy.
- Your PSA is at least 1 ng/mL before starting therapy for metastatic disease.
- You have a smartphone and are comfortable using health apps.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This study looks at how treatment affects your daily life, mood, sleep, and thinking skills. It is for men starting hormone therapy combined with another drug for prostate cancer that has spread.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.